This discussion combines a discussion of the role Fibroblast Growth Factors (FGFs) play in the liver and human body in general, followed by a discussion of what this implies for drug development in general and some of the specific agents currently in testing or market:
0:15 – Opening quotes – Stephen Harrison, Arun Sanyal, Roger Green
1:51 – Episode begins
3:02 – Meet Professor Arun Sanyal
4:27 – Quick Look at Health Systems and Policy: India, UK, future episodes – Arun, Louise Campbell, Roger
7:58 – Icebreaker and episode set-up – Roger and panel
12:43 – Efruxifermin trials – Stephen Harrison
17:42 – How FGFs work — Arun Sanyal
20:51 – Liver pathophysiology and insulin resistance — Stephen and Arun
27:56 – Q & A comparing agents in development – Roger, Louise Campbell, Arun and Stephen
42:05 – Roger offers two choices for the episode’s Final Question. Arun provides an exceptionally thoughtful and thought-provoking answer.
The discussion itself includes three elements: first, a discussion of recent efruxifermin trials; second, a discussion of how FGFs work in the liver and rest of the body; and third, comparing and contrasting the various FGF-21 and FGF-19 drugs that are in development (or have been discontinued).